Dextera Surgical’s MicroCutter 5/80 Enables Shorter Hospital Stays Through Less Invasive Lobectomy
March 06 2017 - 8:30AM
Business Wire
-- Data Presented at Scandinavian Society
for Research in Cardiothoracic Surgery --
Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the
smallest-profile and most maneuverable articulating surgical
stapling platform on the market for minimally invasive surgery,
today announced that Marco Nardini, M.D., from James Cook
University Hospital in Middlesbrough, UK, presented the latest data
on the results of 82 patients undergoing Microlobectomy. The data
demonstrated that for Microlobectomy procedures, the median
hospital stay is reduced by at least two days when compared to
traditional open lobectomy procedures, with over 20 percent of
patients going home the day after surgery.
“The Microlobectomy procedure, enabled by the MicroCutter 5/80
surgical stapler, due to the slim profile of the five-millimeter
diameter with 80 degrees of articulation, reduces postoperative
pain and complications compared to traditional open procedures and
overall, improves a patient’s recovery after a major lung
resection,” commented Dr. Nardini. “These data further support what
surgeons around the world are experiencing when performing the
Microlobectomy – that the less invasive nature of this procedure
shortens hospital stays when compared to a traditional open
lobectomy, with 20.7% of patients able to return home within 24
hours.”
For the 82 patients undergoing a Microlobectomy, the median
length of hospital stay was three days, with 17 patients (20.7%)
discharged the day after surgery and an additional 14 patients
(17%) discharged two days after surgery. Data were presented at the
Scandinavian Society for Research in Cardiothoracic Surgery 2017
held in Geilo, Norway.
Liam Burns, vice president worldwide sales and marketing of
Dextera Surgical, commented, “The interest in the presentation at
the meeting reflects the global interest in technologies like the
MicroCutter 5/80 that enable less invasive approaches to lobectomy
that may accelerate the adoption of video-assisted thoracic surgery
(VATS) techniques and other surgical procedures.”
MicroCutter Indication Information
The MicroCutter 5/80 Stapler is manufactured and cleared for use
in the United States for transection and resection in
multiple open or minimally invasive urologic, thoracic and
pediatric surgical procedures, as well as application for
transection, resection and/or creation of anastomoses in the small
and large intestine, and the transection of the appendix. The
MicroCutter 5/80 may be used with both MicroCutter 30 White Reloads
in vascular/thin tissue and MicroCutter 30 Blue Reloads for
standard tissue.
About Dextera Surgical
Dextera Surgical (Nasdaq:DXTR) designs and manufactures
proprietary stapling devices for minimally invasive surgical
procedures. In the U.S., surgical staplers are routinely used in
more than one million minimally invasive laparoscopic,
video-assisted or robotic-assisted surgical procedures
annually.
Dextera Surgical also markets the only automated
anastomosis devices for coronary artery bypass graft (CABG) surgery
on the market today: the C-Port® Distal Anastomosis Systems and
PAS-Port® Proximal Anastomosis System. These products, sold
by Dextera Surgical under the Cardica brand name, have
demonstrated long-term reliable clinical performance for more than
a decade.
Forward-Looking Statements
The statements in this press release regarding Dextera
Surgical’s expectations as to the benefits of using the MicroCutter
5/80 are "forward-looking statements." There are a number of
important factors that could cause Dextera Surgical’s results to
differ materially from those indicated by these forward-looking
statements, including the risks detailed from time to time in
Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended December 31, 2016, under the caption
“Risk Factors.” Dextera Surgical expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to
read Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170306005412/en/
Dextera Surgical Inc.Bob Newell, 650-331-7133Vice President,
Finance and Chief Financial
Officerinvestors@dexterasurgical.com